Download MendeleyPharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3.
Murray, J.K., Qian, Y.X., Liu, B., Elliott, R., Aral, J., Park, C., Zhang, X., Stenkilsson, M., Salyers, K., Rose, M., Li, H., Yu, S., Andrews, K.L., Colombero, A., Werner, J., Gaida, K., Sickmier, E.A., Miu, P., Itano, A., McGivern, J., Gegg, C.V., Sullivan, J.K., Miranda, L.P.(2015) J Med Chem 58: 6784-6802
- PubMed: 26288216
- DOI: https://doi.org/10.1021/acs.jmedchem.5b00495
- Primary Citation of Related Structures:
4Z7P - PubMed Abstract:
To realize the medicinal potential of peptide toxins, naturally occurring disulfide-rich peptides, as ion channel antagonists, more efficient pharmaceutical optimization technologies must be developed. Here, we show that the therapeutic properties of multiple cysteine toxin peptides can be rapidly and substantially improved by combining direct chemical strategies with high-throughput electrophysiology. We applied whole-molecule, brute-force, structure-activity analoging to ShK, a peptide toxin from the sea anemone Stichodactyla helianthus that inhibits the voltage-gated potassium ion channel Kv1.3, to effectively discover critical structural changes for 15× selectivity against the closely related neuronal ion channel Kv1.1. Subsequent site-specific polymer conjugation resulted in an exquisitely selective Kv1.3 antagonist (>1000× over Kv1.1) with picomolar functional activity in whole blood and a pharmacokinetic profile suitable for weekly administration in primates. The pharmacological potential of the optimized toxin peptide was demonstrated by potent and sustained inhibition of cytokine secretion from T cells, a therapeutic target for autoimmune diseases, in cynomolgus monkeys.
Organizational Affiliation:
Therapeutic Discovery, Amgen Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.
